[{"id":"447ed126-6f5f-4987-b043-27e335f9b442","acronym":"C1763102","url":"https://clinicaltrials.gov/study/NCT05602363","created_at":"2024-01-29T15:19:20.293Z","updated_at":"2025-02-25T14:09:14.782Z","phase":"Phase 1","brief_title":"AS-1763 in Patients With Previously Treated CLL/SLL or Non-Hodgkin Lymphoma","source_id_and_acronym":"NCT05602363 - C1763102","lead_sponsor":"Carna Biosciences, Inc.","biomarkers":" PLCG2","pipe":" | ","alterations":" PLCG2 mutation","tags":["PLCG2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PLCG2 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e docirbrutinib (AS-1763)"],"overall_status":"Recruiting","enrollment":" Enrollment 120","initiation":"Initiation: 08/01/2023","start_date":" 08/01/2023","primary_txt":" Primary completion: 09/01/2027","primary_completion_date":" 09/01/2027","study_txt":" Completion: 09/01/2027","study_completion_date":" 09/01/2027","last_update_posted":"2024-11-01"},{"id":"2a05375a-5452-4690-a731-769e2628d4de","acronym":"TRANSCEND-CLL-004","url":"https://clinicaltrials.gov/study/NCT03331198","created_at":"2021-01-18T16:27:01.921Z","updated_at":"2024-07-02T16:34:59.670Z","phase":"Phase 1/2","brief_title":"Study Evaluating Safety and Efficacy of JCAR017 in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL)","source_id_and_acronym":"NCT03331198 - TRANSCEND-CLL-004","lead_sponsor":"Juno Therapeutics, a Subsidiary of Celgene","biomarkers":" PLCG2 • CD5","pipe":" | ","alterations":" CD19 positive • PLCG2 mutation","tags":["PLCG2 • CD5"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD19 positive • PLCG2 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Venclexta (venetoclax) • Imbruvica (ibrutinib) • Breyanzi (lisocabtagene maraleucel)"],"overall_status":"Recruiting","enrollment":" Enrollment 209","initiation":"Initiation: 11/27/2017","start_date":" 11/27/2017","primary_txt":" Primary completion: 11/26/2027","primary_completion_date":" 11/26/2027","study_txt":" Completion: 11/26/2027","study_completion_date":" 11/26/2027","last_update_posted":"2024-05-31"}]